全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

更多...

Metastatic Hepatocellular Carcinoma in a Non-Cirrhotic Liver without Viral Hepatitis: A Case Report and Literature Review

DOI: 10.4236/jct.2026.171007, PP. 51-60

Keywords: Hepatocellular Carcinoma, Non-Cirrhotic Liver, Absence of Viral Hepatitis, Metastatic Disease, Systemic Therapy

Full-Text   Cite this paper   Add to My Lib

Abstract:

Background: Hepatocellular carcinoma (HCC) usually develops in the setting of cirrhosis or chronic liver disease. Its occurrence in a non-cirrhotic liver and in the absence of viral hepatitis is rare and represents a diagnostic challenge due to the lack of risk factors and routine surveillance. Case Presentation: We report the case of a 45-year-old patient with no history of chronic liver disease and no infection with hepatitis B or C viruses, who presented with right upper quadrant pain and deterioration of general condition. Laboratory investigations showed preserved liver function and normal alpha-fetoprotein levels. Liver imaging revealed a hepatic mass in a liver with normal morphology, showing arterial enhancement with portal washout, associated with multiple pulmonary lesions, confirming the metastatic nature of the disease. A liver biopsy confirmed the diagnosis of metastatic hepatocellular carcinoma. The patient was treated with sorafenib, with a favorable clinical and radiological response. Conclusion: This case illustrates a rare presentation of HCC arising in a non-cirrhotic liver, metastatic at diagnosis, in the absence of viral hepatitis, and occurring in a relatively young patient. It highlights the importance of considering this diagnosis even in the absence of classical risk factors and underscores the role of systemic therapies in medical oncology.

References

[1]  Desai, A., Sandhu, S., Lai, J. and Sandhu, D.S. (2019) Hepatocellular Carcinoma in Non-Cirrhotic Liver: A Comprehensive Review. World Journal of Hepatology, 11, 1-18.
https://doi.org/10.4254/wjh.v11.i1.1
[2]  Aryan, M., Ruli, T. and Shoreibah, M. (2024) HCC in Patients without Cirrhosis: A Review. Clinical Liver Disease, 23, e0224.
https://doi.org/10.1097/cld.0000000000000224
[3]  Sato-Espinoza, K., Valdivia-Herrera, M., Chotiprasidhi, P. and Diaz-Ferrer, J. (2025) Hepatocellular Carcinoma in Patients without Cirrhosis. World Journal of Gastroenterology, 31, Article ID: 107100.
https://doi.org/10.3748/wjg.v31.i23.107100
[4]  Llovet, J.M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J., et al. (2008) Sorafenib in Advanced Hepatocellular Carcinoma. New England Journal of Medicine, 359, 378-390.
https://doi.org/10.1056/nejmoa0708857
[5]  Finn, R.S., Qin, S., Ikeda, M., Galle, P.R., Ducreux, M., Kim, T., et al. (2020) Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. New England Journal of Medicine, 382, 1894-1905.
https://doi.org/10.1056/nejmoa1915745
[6]  Abou-Alfa, G.K., Lau, G., Kudo, M., et al. (2022) Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma. Journal of Clinical Oncology, 40, 336-345.
[7]  Schütte, K., Bornschein, J. and Malfertheiner, P. (2009) Hepatocellular Carcinoma—Epidemiological Trends and Risk Factors. Digestive Diseases, 27, 80-92.
https://doi.org/10.1159/000218339
[8]  Matsumoto, I., Shirakawa, S., Shinzeki, M., Asari, S., Goto, T., Ajiki, T., et al. (2013) 18-Fluorodeoxyglucose Positron Emission Tomography Does Not Aid in Diagnosis of Pancreatic Ductal Adenocarcinoma. Clinical Gastroenterology and Hepatology, 11, 712-718.
https://doi.org/10.1016/j.cgh.2012.12.033
[9]  Piscaglia, F., Svegliati‐Baroni, G., Barchetti, A., Pecorelli, A., Marinelli, S., Tiribelli, C., et al. (2016) Clinical Patterns of Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease: A Multicenter Prospective Study. Hepatology, 63, 827-838.
https://doi.org/10.1002/hep.28368
[10]  Karaoğullarından, Ü., Aydın, Y., Yılmaz, B., et al. (2023) Hepatocellular Carcinoma in Cirrhotic versus Non-Cirrhotic Livers: Clinical Features and Prognosis. Turkish Journal of Gastroenterology, 34, 145-152.
[11]  Galle, P.R., Forner, A., Llovet, J.M., Mazzaferro, V., Piscaglia, F., Raoul, J., et al. (2018) EASL Clinical Practice Guidelines: Management of Hepatocellular Carcinoma. Journal of Hepatology, 69, 182-236.
https://doi.org/10.1016/j.jhep.2018.03.019
[12]  Reig, M., Rimola, J., Torres, F., Darnell, A., Rodriguez-Lope, C., Forner, A., et al. (2013) Postprogression Survival of Patients with Advanced Hepatocellular Carcinoma: Rationale for Second-Line Trial Design. Hepatology, 58, 2023-2031.
https://doi.org/10.1002/hep.26586

Full-Text

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133